ACUR SEC-arkiveringar - Acura Pharmaceuticals, Inc.- Årsredovisning, Fullmaktsutlåtande, prospekt

Grundläggande statistik

CIK

786947

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Acura Pharmaceuticals, Inc.

SEC Filings (Chronological Order)

Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.

September 4, 2025	EX-99.1	Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Exhibit 99.1 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal Original Secured Promissory Note Additional Loans to be included: 11/10/2022 $ 2,319,279 $ 2,319,279 Loans #1 dated 12/22/2022 through Loan #26 dated 12/12/2024 $ 4,625,000 $ 6,944,279 Loan #27 1/13/2025 $ 125,
September 4, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): September 3, 2025 ACURA PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): September 3, 2025 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of incorporation or orga
August 19, 2025	NT 10-Q	Acura Pharmaceuticals, Inc. (Name of Registrant as Specified in Charter) OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 1-10113 CUSIP NUMBER NOTIFICATION OF LATE FILING 00509L 802 (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K [√ ] Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: June 30, 20
July 21, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): July 18, 2025 ACURA PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): July 18, 2025 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of incorporation or organiza
July 21, 2025	EX-99.1	ACURA PHARMACEUTICALS, INC. Exhibit 99.1 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal Original Secured Promissory Note 11/10/2022 $ 2,319,279 $ 2,319,279 Additional Loans to be included: Loans #1 dated 12/22/2022 through Loan #26 dated 12/12/2024 $ 4,625,000 $ 6,944,279 Loan #27 1/13/2025 $ 125,
June 24, 2025	EX-99.1	Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Exhibit 99.1 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal Original Secured Promissory Note 11/10/2022 $ 2,319,279 $ 2,319,279 Additional Loans to be included: Loans #1 dated 12/22/2022 through Loan #26 dated 12/12/2024 $ 4,625,000 $ 6,944,279 Loan #27 1/13/2025 $ 125,
June 24, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): June 20, 2025 ACURA PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): June 20, 2025 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of incorporation or organiza
May 30, 2025	EX-99.2	AMENDMENT #12 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT Exhibit 99.2 AMENDMENT #12 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This AMENDMENT #12 (this "Amendment") TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the "Agreement") dated June 28, 2019 between Acura Pharmaceuticals, Inc. ("Acura"), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma, LLC (
May 30, 2025	EX-99.1	Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Exhibit 99.1 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal Original Secured Promissory Note 11/10/2022 $2,319,279 $2,319,279 Additional Loans to be included: Loans #1 dated 12/22/2022 through Loan #26 dated 12/12/2024 $ 4,625,000 $ 6,944,279 Loan #27 1/13/2025 $ 125,00
May 30, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): May 29, 2025 ACURA PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): May 29, 2025 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of incorporation or organizat
May 30, 2025	EX-99.4	AMENDMENT #4 COMMON STOCK PURCHASE WARRANT Exhibit 99.4 AMENDMENT #4 COMMON STOCK PURCHASE WARRANT This AMENDMENT #4 (this “Amendment”) TO COMMON STOCK PURCHASE WARRANT (the “Warrant”) dated June 28, 2019 between Acura Pharmaceuticals, Inc. (“Acura”), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma, LLC (“AD Pharma”), a Kentucky limited liability company, h
May 30, 2025	EX-99.3	AMENDMENT #6 AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE Exhibit 99.3 AMENDMENT #6 AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE This AMENDMENT #6 (this “Amendment”) TO AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSSORY NOTE (the “Note”) dated November 10, 2022 between Acura Pharmaceuticals, Inc. (“Acura”), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma
May 21, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): May 15, 2025 ACURA PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): May 15, 2025 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of incorporation or organizat
May 14, 2025	NT 10-Q	Acura Pharmaceuticals, Inc. (Name of Registrant as Specified in Charter) OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 1-10113 CUSIP NUMBER NOTIFICATION OF LATE FILING 00509L 802 (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K [√ ] Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: March 31, 2
April 23, 2025	EX-99.1	Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Exhibit 99.1 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal Original Secured Promissory Note 11/10/2022 $ 2,319,279 $ 2,319,279 Additional Loans to be included: Loans #1 dated 12/22/2022 through Loan #26 dated 12/12/2024 $ 4,625,000 $ 6,944,279 Loan #27 1/13/2025 $ 125,
April 23, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): April 18, 2025 ACURA PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): April 18, 2025 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of incorporation or organiz
March 26, 2025	NT 10-K	Acura Pharmaceuticals, Inc. (Name of Registrant as Specified in Charter) OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 1-10113 CUSIP NUMBER NOTIFICATION OF LATE FILING 00509L 802 (Check one): [√ ] Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: December 31
March 4, 2025	EX-99.3	AMENDMENT #5 AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE Exhibit 99.3 AMENDMENT #5 AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE This AMENDMENT #5 (this “Amendment”) TO AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSSORY NOTE (the “Note”) dated November 10, 2022 between Acura Pharmaceuticals, Inc. (“Acura”), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma
March 4, 2025	EX-99.4	AMENDMENT #3 COMMON STOCK PURCHASE WARRANT Exhibit 99.4 AMENDMENT #3 COMMON STOCK PURCHASE WARRANT This AMENDMENT #1 (this “Amendment”) TO COMMON STOCK PURCHASE WARRANT (the “Warrant”) dated June 28, 2019 between Acura Pharmaceuticals, Inc. (“Acura”), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma, LLC (“AD Pharma”), a Kentucky limited liability company, h
March 4, 2025	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): February 28, 2025 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of incorporation or orga
March 4, 2025	EX-99.2	AMENDMENT #11 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT Exhibit 99.2 AMENDMENT #11 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This AMENDMENT #11 (this "Amendment") TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the "Agreement") dated June 28, 2019 between Acura Pharmaceuticals, Inc. ("Acura"), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma, LLC (
March 4, 2025	EX-99.1	Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Exhibit 99.1 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal Original Secured Promissory Note 11/10/2022 $ 2,319,279 $ 2,319,279 Additional Loans to be included: Loans #1 dated 12/22/2022 through Loan #26 dated 12/12/2024 $ 4,625,000 $ 6,944,279 Loan #27 1/13/2025 $ 125,
January 24, 2025	EX-99.1	EX-99.1 Exhibit 99.1 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal Original Secured Promissory Note 11/10/2022 $ 2,319,279 $ 2,319,279 Additional loans to be included: Loan #1 12/22/2022 $ 250,000 $ 2,569,279 Loan #2 1/19/2023 $ 250,000 $ 2,819,279 Loan #3 2/22/2023 $ 250,000
January 24, 2025	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): January 13, 2025 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of incorporation or organ
December 16, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): December 12, 2024 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of incorporation or orga
December 16, 2024	EX-99.1	Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 Exhibit 99.1 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal Original Secured Promissory Note 11/10/2022 $2,319,279 $2,319,279 Additional loans to be included: Loan #1 12/22/2022 $ 250,000 $ 2,569,279 Loan #2 1/19/2023 $ 250,000 $ 2,819,279 Loan #3 2/22/2023 $ 250,000 $
November 21, 2024	NT 10-Q	Acura Pharmaceuticals, Inc. (Name of Registrant as Specified in Charter) OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 1-10113 CUSIP NUMBER NOTIFICATION OF LATE FILING 00509L 802 (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K [√ ] Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: September 3
November 4, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): November 2, 2024 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of incorporation or organ
November 4, 2024	EX-99.2	AMENDMENT #10 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT Exhibit 99.2 AMENDMENT #10 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This AMENDMENT #10 (this "Amendment") TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the "Agreement") dated June 28, 2019 between Acura Pharmaceuticals, Inc. ("Acura"), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma, LLC (
November 4, 2024	EX-99.3	AMENDMENT #4 AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE Exhibit 99.3 AMENDMENT #4 AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE This AMENDMENT #4 (this “Amendment”) TO AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSSORY NOTE (the “Note”) dated November 10, 2022 between Acura Pharmaceuticals, Inc. (“Acura”), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma
November 4, 2024	EX-99.4	AMENDMENT #2 COMMON STOCK PURCHASE WARRANT Exhibit 99.4 AMENDMENT #2 COMMON STOCK PURCHASE WARRANT This AMENDMENT #1 (this “Amendment”) TO COMMON STOCK PURCHASE WARRANT (the “Warrant”) dated June 28, 2019 between Acura Pharmaceuticals, Inc. (“Acura”), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma, LLC (“AD Pharma”), a Kentucky limited liability company, h
November 4, 2024	EX-99.1	ACURA PHARMACEUTICALS, INC. Exhibit 99.1 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal Original Secured Promissory Note 11/10/2022 $2,319,279 $2,319,279 Additional loans to be included: Loan #1 12/22/2022 $250,000 $2,569,279 Loan #2 1/19/2023 $250,000 $2,819,279 Loan #3 2/22/2023 $250,000 $3,069,
October 2, 2024	EX-99.1	Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Exhibit 99.1 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal Original Secured Promissory Note Additional loans to be included: 11/10/2022 $ 2,319,279 $ 2,319,279 Loan #1 12/22/2022 $ 250,000 $ 2,569,279 Loan #2 1/19/2023 $ 250,000 $ 2,819,279 Loan #3 2/22/2023 $ 250,000
October 2, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): September 30, 2024 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of incorporation or org
August 9, 2024	NT 10-Q	Acura Pharmaceuticals, Inc. (Name of Registrant as Specified in Charter) OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 1-10113 CUSIP NUMBER NOTIFICATION OF LATE FILING 00509L 802 (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K [√ ] Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: June 30, 20
July 26, 2024	EX-99.1	Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 EX-99.1 2 tm2420298d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal Original Secured Promissory Note 11/10/2022 $2,319,279 $2,319,279 Additional loans to be included: Loan #1 12/22/2022 $250,000 $2,569,279 Loan #2 1/19/2023 $250,000
July 26, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): July 22, 2024 ACURA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 1-10113 11-0853640 (State or other jurisdiction of incorporation (Commission
July 2, 2024	EX-99.1	Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 Exhibit 99.1 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal Original Secured Promissory Note 11/10/2022 $ 2,319,279 $ 2,319,279 Additional loans to be included: Loan #1 12/22/2022 $ 250,000 $ 2,569,279 Loan #2 1/19/2023 $ 250,000 $ 2,819,279 Loan #3 2/22/2023 $ 250,000
July 2, 2024	EX-99.4	AMENDMENT #1 COMMON STOCK PURCHASE WARRANT Exhibit 99.4 AMENDMENT #1 COMMON STOCK PURCHASE WARRANT This AMENDMENT #1 (this “Amendment”) TO COMMON STOCK PURCHASE WARRANT (the “Warrant”) dated June 28, 2019 between Acura Pharmaceuticals, Inc. (“Acura”), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma, LLC (“AD Pharma”), a Kentucky limited liability company, h
July 2, 2024	EX-99.2	AMENDMENT #9 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT Exhibit 99.2 AMENDMENT #9 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This AMENDMENT #9 (this "Amendment") TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the "Agreement") dated June 28, 2019 between Acura Pharmaceuticals, Inc. ("Acura"), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma, LLC ("A
July 2, 2024	EX-99.3	AMENDMENT #3 AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE Exhibit 99.3 AMENDMENT #3 AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE This AMENDMENT #3 (this “Amendment”) TO AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSSORY NOTE (the “Note”) dated November 10, 2022 between Acura Pharmaceuticals, Inc. (“Acura”), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma
July 2, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): June 28, 2024 ACURA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 1-10113 11-0853640 (State or other jurisdiction of incorporation (Commission
June 4, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): May 31, 2024 ACURA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 1-10113 11-0853640 (State or other jurisdiction of incorporation (Commission
May 15, 2024	NT 10-Q	Acura Pharmaceuticals, Inc. (Name of Registrant as Specified in Charter) OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 1-10113 CUSIP NUMBER NOTIFICATION OF LATE FILING 00509L 802 (Check one): o Form 10-K o Form 20-F o Form 11-K [√ ] Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period Ended: March 31, 2
May 14, 2024	EX-99.1	Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Exhibit 99.1 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal Original Secured Promissory Note Additional loans to be included: 11/10/2022 $ 2,319,279 $ 2,319,279 Loan #1 12/22/2022 $ 250,000 $ 2,569,279 Loan #2 1/19/2023 $ 250,000 $ 2,819,279 Loan #3 2/22/2023 $ 250,000
May 14, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): May 10, 2024 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number) (
April 1, 2024	NT 10-K	Acura Pharmaceuticals, Inc. (Name of Registrant as Specified in Charter) OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 1-10113 CUSIP NUMBER NOTIFICATION OF LATE FILING 00509L 802 (Check one): [√ ] Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: December 31
March 26, 2024	EX-99.3	AMENDMENT #2 AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE Exhibit 99.3 AMENDMENT #2 AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE This AMENDMENT #2 (this “Amendment”) TO AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSSORY NOTE (the “Note”) dated November 10, 2022 between Acura Pharmaceuticals, Inc. (“Acura”), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma
March 26, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): March 25, 2024 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number)
March 26, 2024	EX-99.2	AMENDMENT #8 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT Exhibit 99.2 AMENDMENT #8 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This AMENDMENT #8 (this "Amendment") TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the "Agreement") dated June 28, 2019 between Acura Pharmaceuticals, Inc. ("Acura"), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma, LLC ("A
March 18, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): March 14, 2024 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number)
March 18, 2024	EX-99.1	Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Exhibit 99.1 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal Original Secured Promissory Note 11/10/2022 $ 2,319,279 $ 2,319,279 Additional loans to be included: Loan #1 12/22/2022 $ 250,000 $ 2,569,279 Loan #2 1/19/2023 $ 250,000 $ 2,819,279 Loan #3 2/22/2023 $ 250,000
February 14, 2024	EX-99.1	Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Exhibit 99.1 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal Original Secured Promissory Note 11/10/2022 $ 2,319,279 $ 2,319,279 Additional loans to be included: Loan #1 12/22/2022 $ 250,000 $ 2,569,279 Loan #2 1/19/2023 $ 250,000 $ 2,819,279 Loan #3 2/22/2023 $ 250,000
February 14, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): February 14, 2024 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Numb
February 2, 2024	EX-16.1	U.S. Securities and Exchange Commission 100 F Street, NE Exhibit 16.1 U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549-7561 Re: Acura Pharmaceuticals, Inc. SEC File. 1-10113 On January 30, 2024, our appointment as auditor for Acura Pharmaceuticals, Inc. ceased. We have read Acura Pharmaceuticals, Inc’s statements included under Item 4.01 of its Form 8-K/A dated February 2, 2024 and agree with such statements, insofar as th
February 2, 2024	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): January 30, 2024 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Numbe
January 10, 2024	EX-99.1	Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 Exhibit 99.1 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal Original Secured Promissory Note 11/10/2022 $ 2,319,279 $ 2,319,279 Additional loans to be included: Loan #1 12/22/2022 $ 250,000 $ 2,569,279 Loan #2 1/19/2023 $ 250,000 $ 2,819,279 Loan #3 2/22/2023 $ 250,000
January 10, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): January 8, 2024 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number
December 21, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): December 7, 2023 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Numbe
December 21, 2023	EX-99.1	AMENDMENT #1 AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE Exhibit 99.1 AMENDMENT #1 AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE This AMENDMENT #1 (this “Amendment”) TO AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSSORY NOTE (the “Note”) dated November 10, 2022 between Acura Pharmaceuticals, Inc. (“Acura”), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma
December 6, 2023	EX-99.2	AMENDMENT #7 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT Exhibit 99.2 AMENDMENT #7 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This AMENDMENT #7 (this "Amendment") TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the "Agreement") dated June 28, 2019 between Acura Pharmaceuticals, Inc. ("Acura"), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma, LLC ("A
December 6, 2023	EX-99.1	ACURA PHARMACEUTICALS, INC. Exhibit 99.1 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal Original Secured Promissory Note 11/10/2022 $2,319,279 $2,319,279 Additional loans to be included: Loan #1 12/22/2022 $250,000 $2,569,279 Loan #2 1/19/2023 $250,000 $2,819,279 Loan #3 2/22/2023 $250,000 $3,069,
December 6, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): December 4, 2023 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Numbe
November 3, 2023	NT 10-Q	Acura Pharmaceuticals, Inc. (Name of Registrant as Specified in Charter) OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 1-10113 CUSIP NUMBER NOTIFICATION OF LATE FILING 00509L 802 (Check one): o Form 10-K o Form 20-F o Form 11-K [√] Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period Ended: September 30
October 12, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): October 10, 2023 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of incorporation or organ
October 12, 2023	EX-99.1	Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 Exhibit 99.1 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal Original Secured Promissory Note 11/10/2022 $ 2,319,279 $ 2,319,279 Additional loans to be included: Loan #1 12/22/2022 $ 250,000 $ 2,569,279 Loan #2 1/19/2023 $ 250,000 $ 2,819,279 Loan #3 2/22/2023 $ 250,000
September 25, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): September 22, 2023 ACURA PHARMAC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): September 22, 2023 ACURA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 1-10113 11-0853640 (State or other jurisdiction of incorporation) (Comm
September 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): August 30, 2023 ACURA PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): August 30, 2023 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number
September 1, 2023	EX-99.1	Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 Exhibit 99.1 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal Original Secured Promissory Note 11/10/2022 $ 2,319,279 $ 2,319,279 Additional loans to be included: Loan #1 12/22/2022 $ 250,000 $ 2,569,279 Loan #2 1/19/2023 $ 250,000 $ 2,819,279 Loan #3 2/22/2023 $ 250,000
August 31, 2023	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): August 31, 2023 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number
August 30, 2023	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): August 30, 2023 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number
August 16, 2023	8-K	Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): August 14, 2023 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number
August 10, 2023	NT 10-Q	Acura Pharmaceuticals, Inc. (Name of Registrant as Specified in Charter) OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 1-10113 CUSIP NUMBER NOTIFICATION OF LATE FILING 00509L 802 (Check one): o Form 10-K o Form 20-F o Form 11-K [√] Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period Ended: June 30, 202
July 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): July 28, 2023 ACURA PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): July 28, 2023 ACURA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 1-10113 11-0853640 (State or other jurisdiction of incorporation) (Commissio
July 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): July 28, 2023 ACURA PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): July 28, 2023 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number)
July 28, 2023	EX-99.1	Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 Exhibit 99.1 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal Original Secured Promissory Note 11/10/2022 $ 2,319,279 $ 2,319,279 Additional loans to be included: Loan #1 12/22/2022 $ 250,000 $ 2,569,279 Loan #2 1/19/2023 $ 250,000 $ 2,819,279 Loan #3 2/22/2023 $ 250,000
July 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): July 10, 2023 ACURA PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): July 10, 2023 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number)
July 13, 2023	EX-99.1	Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 Exhibit 99.1 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal Original Secured Promissory Note 11/10/2022 $ 2,319,279 $ 2,319,279 Additional loans to be included: Loan #1 12/22/2022 $ 250,000 $ 2,569,279 Loan #2 1/19/2023 $ 250,000 $ 2,819,279 Loan #3 2/22/2023 $ 250,000 $
June 30, 2023	EX-10.58	Third Amendment to the Amended License, Development and Commercialization Agreement is made and entered into as of February 28, 2022 by the Registrant and between Abuse Deterrent Pharma, LLC. Exhibit 10.58 AMENDMENT #3 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This AMENDMENT (the “Amendment #3”) to the LICENSE, DEVELOPMENT and COMMERCIALIZATION AGREEMENT (the “Agreement”) dated June 28, 2019 between Acura Pharmaceuticals, Inc. (“Acura”), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma, LLC
June 30, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): June 30, 2023 ACURA PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): June 30, 2023 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number)
June 30, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended DECEMBER 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-10113
June 30, 2023	EX-10.70	Amended Loan Schedule to the Amended, Consolidated and Restated Secured Promissory Note dated November 10, 2022 issued to Abuse Deterrent Pharma, LLC on May 19, 2023 aggregating $3,469,279. Exhibit 10.70 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal Original Secured Promissory Note 11/10/2022 $ 2,319,279 $ 2,319,279 Additional loans to be included: Loan #1 12/22/2022 $ 250,000 $ 2,569,279 Loan #2 1/19/2023 $ 250,000 $ 2,819,279 Loan #3 2/22/2023 $ 250,000
June 30, 2023	EX-99.1	ACURA PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) Exhibit 99.1 ACURA PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (audited) (audited) December 31, December 31, 2021 2020 Assets – current $ 372 $ 1,179 Property, plant and equipment, net 438 484 Other assets 50 73 Total assets $ 860 $ 1,736 Other liabilities - current $ 515 $ 680 Loan under CARES Act - current - 164 Accrued interest to related party – current - 678 Con
June 30, 2023	EX-16.1	Letter of BDO to the Securities and Exchange Commission dated June 30, 2023 (filed herewith). Exhibit 16.1 Tel:    312-856-9100 Fax:   312-856-1379 www.bdo.com 330 N Wabash, Suite 3200 Chicago, IL 60611 June 30, 2023 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on June 26, 2023, to be filed by our former client, Acura Pharmaceuticals, Inc. We agree with the
June 30, 2023	EX-10.68	Amended, Consolidated and Restated Secured Promissory Note dated November 10, 2022 issued to John Schutte. Exhibit 10.68 AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE November 10, 2022 FOR VALUE RECEIVED, ACURA PHARMACEUTICALS, INC., a New York corporation having its principal place of business at 616 N. North Court, Suite 120, Palatine, Illinois, as maker (the “Company”), hereby unconditionally promises to pay to the order of Abuse Deterrent Pharma, LLC, a Kentucky limited liability compa
June 30, 2023	EX-10.54	Amendment #2 to the License, Development and Commercialization Agreement is made and entered into as of June 17, 2021 by the Registrant and between Abuse Deterrent Pharma, LLC. Exhibit 10.54 AMENDMENT #2 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This AMENDMENT (the “Amendment #2”) to the LICENSE, DEVELOPMENT and COMMERCIALIZATION AGREEMENT (the “Agreement”) dated June 28, 2019 between Acura Pharmaceuticals, Inc. (“Acura”), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma, LLC
June 30, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): June 30, 2023 ACURA PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): June 30, 2023 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number)
June 28, 2023	EX-99.1	AMENDMENT #6 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT Exhibit 99.1   AMENDMENT #6 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT   This AMENDMENT #6 (this “Amendment”) TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”) dated June 28, 2019 between Acura Pharmaceuticals, Inc. (“Acura”), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma, LLC
June 28, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): June 15, 2023 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number)
May 26, 2023	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): May 19, 2023 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number) (
May 15, 2023	NT 10-Q	Acura Pharmaceuticals, Inc. (Name of Registrant as Specified in Charter) OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: April 30, 2022 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 1-10113 CUSIP NUMBER NOTIFICATION OF LATE FILING 00509L 802 (Check one): [ ] Form 10-K [] Form 20-F [] Form 11-K [√] Form 10-Q [] Form 10-D [] Form N-CEN [] Form N-CSR For Period Ended: March
March 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): March 20, 2023 ACURA PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): March 20, 2023 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number)
March 20, 2023	NT 10-K	Acura Pharmaceuticals, Inc. (Name of Registrant as Specified in Charter) NT 10-K 1 tm2310023d1nt10k.htm NT 10-K OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: April 30, 2022 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 1-10113 CUSIP NUMBER NOTIFICATION OF LATE FILING 00509L 802 (Check one): [√ ] Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ F
February 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): February 22, 2023 ACURA PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): February 22, 2023 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Numb
February 13, 2023	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): February 13, 2023 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Numb
February 2, 2023	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): February 2, 2023 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Numbe
January 20, 2023	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): January 19, 2023 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Numbe
December 27, 2022	EX-99.1	AMENDMENT #4 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT EX-99.1 2 tm2233547d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 AMENDMENT #4 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This AMENDMENT #4 (this “Amendment”) TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”) dated June 28, 2019 between Acura Pharmaceuticals, Inc. (“Acura”), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine,
December 27, 2022	EX-99.2	AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE November 10, 2022 Exhibit 99.2 AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE November 10, 2022 FOR VALUE RECEIVED, ACURA PHARMACEUTICALS, INC., a New York corporation having its principal place of business at 616 N. North Court, Suite 120, Palatine, Illinois, as maker (the ?Company?), hereby unconditionally promises to pay to the order of Abuse Deterrent Pharma, LLC, a Kentucky limited liability compan
December 27, 2022	EX-99.3	AMENDMENT #5 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT EX-99.3 4 tm2233547d1ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 AMENDMENT #5 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This AMENDMENT #5 (this “Amendment”) TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”) dated June 28, 2019 between Acura Pharmaceuticals, Inc. (“Acura”), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine,
December 27, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): December 15, 2022 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Numb
November 14, 2022	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): November 10, 2022 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Numb
November 4, 2022	NT 10-Q	Acura Pharmaceuticals, Inc. (Name of Registrant as Specified in Charter) OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: April 30, 2022 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 1-10113 CUSIP NUMBER NOTIFICATION OF LATE FILING 00509L 802 (Check one): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: September 30,
October 17, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): October 13, 2022 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Numbe
October 17, 2022	EX-99.1	NEGOTIABLE PROMISSORY NOTE Exhibit 99.1 NEGOTIABLE PROMISSORY NOTE $250,000.00 October 13, 2022 FOR VALUE RECEIVED, Acura Pharmaceuticals, Inc., a New York corporation having its principal place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, as maker (the ?Maker?), hereby unconditionally promises to pay to the order of John Schutte, having an office at c/o MainPointe Pharmaceuticals, LLC, 2604 River Green
September 26, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): September 20, 2022 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Num
September 26, 2022	EX-99.1	NEGOTIABLE PROMISSORY NOTE Exhibit 99.1 NEGOTIABLE PROMISSORY NOTE $150,000.00 September 20, 2022 FOR VALUE RECEIVED, Acura Pharmaceuticals, Inc., a New York corporation having its principal place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, as maker (the ?Maker?), hereby unconditionally promises to pay to the order of John Schutte, having an office at c/o MainPointe Pharmaceuticals, LLC, 2604 River Gre
August 26, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): August 23, 2022 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number
August 26, 2022	EX-99.1	NEGOTIABLE PROMISSORY NOTE Exhibit 99.1 NEGOTIABLE PROMISSORY NOTE $250,000.00 August 23, 2022 FOR VALUE RECEIVED, Acura Pharmaceuticals, Inc., a New York corporation having its principal place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, as maker (the ?Maker?), hereby unconditionally promises to pay to the order of John Schutte, having an office at c/o MainPointe Pharmaceuticals, LLC, 2604 River Green
July 28, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): July 20, 2022 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number)
July 19, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): July 18, 2022 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number)
July 19, 2022	EX-99.1	NEGOTIABLE PROMISSORY NOTE Exhibit 99.1 NEGOTIABLE PROMISSORY NOTE $150,000.00 July 18, 2022 FOR VALUE RECEIVED, Acura Pharmaceuticals, Inc., a New York corporation having its principal place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, as maker (the ?Maker?), hereby unconditionally promises to pay to the order of John Schutte, having an office at c/o MainPointe Pharmaceuticals, LLC, 2604 River Green Ci
July 14, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): July 13, 2022 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number)
July 11, 2022	EX-99.1	NEGOTIABLE PROMISSORY NOTE Exhibit 99.1 NEGOTIABLE PROMISSORY NOTE $150,000.00 July 6, 2022 FOR VALUE RECEIVED, Acura Pharmaceuticals, Inc., a New York corporation having its principal place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, as maker (the ?Maker?), hereby unconditionally promises to pay to the order of John Schutte, having an office at c/o MainPointe Pharmaceuticals, LLC, 2604 River Green Cir
July 11, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): July 6, 2022 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number) (
June 13, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): June 10, 2022 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number)
June 13, 2022	EX-99.1	NEGOTIABLE PROMISSORY NOTE Exhibit 99.1 NEGOTIABLE PROMISSORY NOTE $100,000.00 June 10, 2022 FOR VALUE RECEIVED, Acura Pharmaceuticals, Inc., a New York corporation having its principal place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, as maker (the ?Maker?), hereby unconditionally promises to pay to the order of John Schutte, having an office at c/o MainPointe Pharmaceuticals, LLC, 2604 River Green Ci
May 23, 2022	EX-99.1	NEGOTIABLE PROMISSORY NOTE Exhibit 99.1 NEGOTIABLE PROMISSORY NOTE $100,000.00 May 20, 2022 FOR VALUE RECEIVED, Acura Pharmaceuticals, Inc., a New York corporation having its principal place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, as maker (the ?Maker?), hereby unconditionally promises to pay to the order of John Schutte, having an office at c/o MainPointe Pharmaceuticals, LLC, 2604 River Green Cir
May 23, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): May 20, 2022 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number) (
May 19, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): May 17, 2022 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number) (
May 16, 2022	NT 10-Q	Acura Pharmaceuticals, Inc. (Name of Registrant as Specified in Charter) OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: April 30, 2022 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 1-10113 CUSIP NUMBER NOTIFICATION OF LATE FILING 00509L 802 (Check one): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: March 31, 2022
May 2, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): April 29, 2022 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number)
May 2, 2022	EX-99.1	NEGOTIABLE PROMISSORY NOTE Exhibit 99.1 NEGOTIABLE PROMISSORY NOTE $150,000.00 April 29, 2022 FOR VALUE RECEIVED, Acura Pharmaceuticals, Inc., a New York corporation having its principal place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, as maker (the ?Maker?), hereby unconditionally promises to pay to the order of John Schutte, having an office at c/o MainPointe Pharmaceuticals, LLC, 2604 River Green C
April 4, 2022	EX-99.1	NEGOTIABLE PROMISSORY NOTE Exhibit 99.1 NEGOTIABLE PROMISSORY NOTE $150,000.00 March 31, 2022 FOR VALUE RECEIVED, Acura Pharmaceuticals, Inc., a New York corporation having its principal place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, as maker (the ?Maker?), hereby unconditionally promises to pay to the order of John Schutte, having an office at c/o MainPointe Pharmaceuticals, LLC, 2604 River Green C
April 4, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): March 31, 2022 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number)
March 31, 2022	NT 10-K	PART I — REGISTRANT INFORMATION OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: March 31, 2022 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 1-10113 CUSIP NUMBER NOTIFICATION OF LATE FILING 00509L 802 (Check one): x Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: December 31, 2
March 1, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): February 28, 2022 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Numb
March 1, 2022	EX-99.1	Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03 Amendment Extends NDA Acceptance Date Exhibit 99.1 Acura Pharmaceuticals and AD Pharma Amend License to LIMITx? LTX-03 Amendment Extends NDA Acceptance Date PALATINE, IL, March 1, 2022: Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (?Agreement?) regarding Acura?s LIMITx? LTX-03 product candidate with Abuse Deterrent Pharmaceuticals, LLC (?AD Pharma?)
February 15, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): February 14, 2022 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Numb
February 15, 2022	EX-99.1	Acura Pharmaceuticals Provides Development Update on LTX-03 Exhibit 99.1 Acura Pharmaceuticals Provides Development Update on LTX-03 PALATINE, IL, February 14, 2022: Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced that the LTX-03 (hydrocodone bitartrate and acetaminophen) tablets using Acura?s LIMITx technology manufactured in the three New Drug Application (?NDA?) required registration batches successfully passed testing at the six month time po
February 14, 2022	EX-99.1	JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT Each of the undersigned agrees that (i) the statement on Schedule 13D relating to the Common Stock of Acura Pharmaceuticals, Inc.
February 14, 2022	SC 13D/A	ACUR / Acura Pharmaceuticals, Inc. / ESSEX WOODLANDS HEALTH VENTURES FUND V LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Final Amendment)* Acura Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 4063691 08 7 (CUSIP Number) Martin P. Sutter Essex Woodlands Health Ventures Fund V, L.P. 21 Waterway Avenue, Suite 225 The Woodlands, Tex
February 1, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): January 31, 2022 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Numbe
February 1, 2022	EX-99.1	NEGOTIABLE PROMISSORY NOTE Exhibit 99.1 NEGOTIABLE PROMISSORY NOTE $200,000.00 January 31, 2022 FOR VALUE RECEIVED, Acura Pharmaceuticals, Inc., a New York corporation having its principal place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, as maker (the ?Maker?), hereby unconditionally promises to pay to the order of John Schutte, having an office at c/o MainPointe Pharmaceuticals, LLC, 2604 River Green
January 4, 2022	EX-99.1	NEGOTIABLE PROMISSORY NOTE Exhibit 99.1 NEGOTIABLE PROMISSORY NOTE $125,000.00 January 3, 2022 FOR VALUE RECEIVED, Acura Pharmaceuticals, Inc., a New York corporation having its principal place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, as maker (the ?Maker?), hereby unconditionally promises to pay to the order of John Schutte, having an office at c/o MainPointe Pharmaceuticals, LLC, 2604 River Green
January 4, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): January 3, 2022 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number
December 28, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): December 21, 2021 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Numb
December 28, 2021	EX-99.1	NEGOTIABLE PROMISSORY NOTE Exhibit 99.1 NEGOTIABLE PROMISSORY NOTE $150,000.00 December 21, 2021 FOR VALUE RECEIVED, Acura Pharmaceuticals, Inc., a New York corporation having its principal place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, as maker (the ?Maker?), hereby unconditionally promises to pay to the order of John Schutte, having an office at c/o MainPointe Pharmaceuticals, LLC, 2604 River Gree
November 17, 2021	EX-99.1	Acura Pharmaceuticals Announces Third Quarter 2021 Financial Results Exhibit 99.1 Acura Pharmaceuticals Announces Third Quarter 2021 Financial Results Palatine, IL ? (November 15, 2021) - Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and nine months ended
November 17, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): November 15, 2021 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Numb
November 15, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 17, 2021	EX-99.1	Acura Pharmaceuticals Announces Second Quarter 2021 Financial Results Exhibit 99.1 Acura Pharmaceuticals Announces Second Quarter 2021 Financial Results Palatine, IL ? (August 16, 2021) - Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and six months ended J
August 17, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): August 16, 2021 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number
August 16, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
July 28, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): July 26, 2021 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number)
July 28, 2021	EX-99.1	Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03 Amendment Extends NDA Acceptance Date Exhibit 99.1 Acura Pharmaceuticals and AD Pharma Amend License to LIMITx? LTX-03 Amendment Extends NDA Acceptance Date PALATINE, IL, July 26, 2021: Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (?Agreement?) regarding Acura?s LIMITx? LTX-03 product candidate with Abuse Deterrent Pharma, LLC (?AD Pharma?) to extend
June 28, 2021	SC 13D/A	ACUR / Acura Pharmaceuticals, Inc. / Schutte John - 13D/A2 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* ACURA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00509L802 (CUSIP Number) John Schutte c/o Main Pointe Pharmaceuticals, LLC 2604 River Green Circle Louisville, KY 40206 502-423-0351 (Name, Address and Telephone N
June 14, 2021	EX-99.1	Acura Pharmaceuticals Announces Conversion of Debt Exhibit 99.1 Acura Pharmaceuticals Announces Conversion of Debt PALATINE, IL, June 14, 2021: Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced that Abuse Deterrent Pharma, LLC (?AD Pharma?) has converted the entire principle and accrued interest of its Secured Promissory Note (the ?Note?) with the Company into shares of the Company?s common stock. Effective with this conversion, the Note i
June 14, 2021	8-K	Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): June 9, 2021 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number) (
June 7, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): June 7, 2021 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number) (
June 7, 2021	EX-99.1	Acura Pharmaceuticals Provides Development Update on LTX-03 Exhibit 99.1 Acura Pharmaceuticals Provides Development Update on LTX-03 PALATINE, IL, June 7, 2021: Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced the successful completion of three NDA required registration batches of the to-be-marketed LTX-03 formulation. The LTX-03 tablets were manufactured on commercial scale equipment and passed all requisite quality assurance tests. The LTX-03 ta
June 1, 2021	S-8	As filed with the Securities and Exchange Commission on June 1, 2021. As filed with the Securities and Exchange Commission on June 1, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) New York 11-0853640 (State or Other Jurisdiction of Incorporation or Organization) (IRS Em
June 1, 2021	EX-10.1	Acura Pharmaceuticals, Inc. 2021 Restricted Stock Unit Award Plan EX-10.1 3 tm2117816d1ex10-1.htm EXHIBIT 10.1 EXHIBIT 10.1 2021 restricted Stock Unit Award Plan (EFFECTIVE May 25, 2021) 1. General Description. The Plan provides for grants of restricted stock units to employees, consultants and Non-Employee Directors of the Company and its Subsidiaries. The purpose of the Plan is to attract, motivate and retain experienced and knowledgeable employees and consult
May 27, 2021	EX-10.1	Acura Pharmaceuticals Inc. 2021 Restricted Stock Unit Award Plan. Exhibit 10.1 2021 restricted Stock Unit Award Plan (EFFECTIVE May 25, 2021) 1. General Description. The Plan provides for grants of restricted stock units to employees, consultants and Non-Employee Directors of the Company and its Subsidiaries. The purpose of the Plan is to attract, motivate and retain experienced and knowledgeable employees and consultants by offering additional stock based compe
May 27, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): May 25, 2021 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number) (
May 27, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): May 25, 2021 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of incorporation or organizat
May 18, 2021	EX-99.1	Acura Pharmaceuticals Announces First Quarter Ended March 31, 2021 Financial Results Exhibit 99.1 Acura Pharmaceuticals Announces First Quarter Ended March 31, 2021 Financial Results Palatine, IL ? (May 17, 2021) - Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for its first quarter en
May 18, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): May 17, 2021 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number) (
May 17, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Or ? TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-10113 Acura Pharmaceuticals,
April 12, 2021	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
April 1, 2021	EX-99.1	Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Financial Results Exhibit 99.1 Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Financial Results Palatine, IL – (March 31, 2021) - Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and twelv
April 1, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): March 31, 2021 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number)
March 31, 2021	EX-10.53	Amended License, Development and Commercialization Agreement is made and entered into as of October 16, 2020 by the Registrant and between Abuse Deterrent Pharmaceuticals, LLC. Exhibit 10.53 AMENDMENT TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This AMENDMENT (the ?Amendment?) to the LICENSE, DEVELOPMENT and COMMERCIALIZATION AGREEMENT (the ?Agreement?) dated June 28, 2019 between Acura Pharmaceuticals, Inc. (?Acura?), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma, LLC (?AD
March 31, 2021	10-K	Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-10113 ACURA PHARMACEUTI
November 17, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): November 16, 2020 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Numb
November 17, 2020	EX-99.1	Acura Pharmaceuticals Announces Third Quarter 2020 Financial Results Exhibit 99.1 Acura Pharmaceuticals Announces Third Quarter 2020 Financial Results Palatine, IL ? (November 16, 2020) - Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced today financial resul
November 16, 2020	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Or ¨ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-10113 Acura P
October 29, 2020	EX-99.1	Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03 Amendment Extends NDA Acceptance Date and Expands Agreement Exhibit 99.1 Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03 Amendment Extends NDA Acceptance Date and Expands Agreement PALATINE, IL, October 28, 2020: Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (“Agreement”) regarding Acura’s LIMITx™ LTX-03 product candidate with Abuse Deterrent Pharmaceut
October 29, 2020	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): October 16, 2020 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Numbe
August 17, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): August 14, 2020 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number
August 17, 2020	EX-99.1	Acura Pharmaceuticals Announces Second Quarter 2020 Financial Results Exhibit 99.1 Acura Pharmaceuticals Announces Second Quarter 2020 Financial Results Palatine, IL – (August 14, 2020) - Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced today financial result
August 14, 2020	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 Or ¨ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-10113 Acura Pharma
June 30, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): June 29, 2020 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number)
June 30, 2020	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 Or ¨ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-10113 Acura Pharm
June 30, 2020	EX-99.1	Acura Pharmaceuticals Announces First Quarter 2020 Financial Results Exhibit 99.1 Acura Pharmaceuticals Announces First Quarter 2020 Financial Results Palatine, IL – (June 29, 2020) - Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced today financial results f
May 13, 2020	8-K	Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): May 13, 2020 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State of Other Jurisdiction (Commission File Number) (I.R
April 1, 2020	EX-99.1	Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results Exhibit 99.1 Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results Palatine, IL – (March 30, 2020) - Acura Pharmaceuticals, Inc., a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced today financial results
April 1, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): March 30, 2020 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State of Other Jurisdiction (Commission File Number) (I
March 31, 2020	EX-10.50	License, Development and Commercialization Agreement is made and entered into as of June 28, 2019 by the Registrant and between Abuse Deterrent Pharmaceuticals, LLC (incorporated by reference to Exhibit 10.50 to our Form 10-K filed March 31, 2020). Exhibit 10.50 LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This License, Development and Commercialization Agreement (“Agreement”) is made and entered into as of June 28, 2019 (the “Effective Date”) by and between Abuse Deterrent Pharmaceuticals, LLC, with offices at 333 E. Main Street, Suite 220, Louisville, Kentucky 40202 (“AD Pharma”), and Acura Pharmaceuticals, Inc., with offices at 61
March 31, 2020	NT 10-K	ACUR / Acura Pharmaceuticals, Inc. NT 10-K - - NT 10-K OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 1-10113 CUSIP NUMBER NOTIFICATION OF LATE FILING 00509L 802 (Check one): [√] Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December
March 31, 2020	EX-10.51	Common Stock Warrant issued June 28, 2019 to John Schutte (incorporated by reference to Exhibit 10.51 to our Form 10-K filed March 31, 2020). Exhibit 10.51 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTION 5.3 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATI
March 31, 2020	EX-10.52	Assignment of Promissory Note, Warrant and Security Agreement issued June 28, 2019 by John Schutte to Abuse Deterrent Pharmaceuticals, LLC (incorporated by reference to Exhibit 10.52 to our Form 10-K filed March 31, 2020). Exhibit 10.52 Assignment of Promissory Note, Warrant and Security Agreement For value received, John Schutte (“Assignor”) hereby assigns and transfers to Abuse Deterrent Pharma, LLC, a Kentucky limited liability company (“Assignee”), all of the Assignor’s right, title and interest in and to (i) that certain Amended, Consolidated and Restated Convertible Secured Promissory Note (the “Note”) dated J
March 31, 2020	10-K	ACUR / Acura Pharmaceuticals, Inc. 10-K - Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-10113 ACURA PHARMACEUTI
March 17, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): February 28, 2020 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State of Other Jurisdiction (Commission File Number)
March 17, 2020	EX-99.1	Acura Pharmaceuticals Announces Third Quarter 2019 Financial Results EX-99.1 2 tm2012995d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Acura Pharmaceuticals Announces Third Quarter 2019 Financial Results Palatine, IL – (February 28, 2020) - Acura Pharmaceuticals, Inc., a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse,
February 28, 2020	10-Q	ACUR / Acura Pharmaceuticals, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 Or ¨ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-10113 Acura P
February 28, 2020	EX-10.49	Promissory Note dated June 28, 2019 issued to John Schutte (incorporated by reference to Exhibit 10.49 to our Form 10-Q filed February 20, 2020). Exhibit 10.49 THIS NOTE AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTION 9.2 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER THE SECURITIES ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM
February 12, 2020	EX-99.1	Acura Pharmaceuticals Announces Second Quarter 2019 Financial Results Exhibit 99.1 Acura Pharmaceuticals Announces Second Quarter 2019 Financial Results Palatine, IL – (February 10, 2020) - Acura Pharmaceuticals, Inc., a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced today financial results for the th
February 12, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): February 10, 2020 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State of Other Jurisdiction (Commission File Number)
February 10, 2020	10-Q	ACUR / Acura Pharmaceuticals, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 Or ¨ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-10113 Acura Pharma
February 10, 2020	EX-10.47	Promissory Note dated May 1, 2019 issued to John Schutte (incorporated by reference to Exhibit 10.47 to our Form 10-Q filed February 10, 2020). Exhibit 10.47 PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, ACURA PHARMACEUTICALS, INC., a New York corporation with offices located at 616 N. North Court, Suite 120, Palatine, Illinois (“Borrower”), hereby unconditionally promises to pay to the order of John Schutte c/o MainPointe Pharmaceuticals, LLC, 333 E. Main Street, Louisville, KY 40202 or his
February 10, 2020	EX-10.48	Promissory Note dated June 12, 2019 issued to John Schutte (incorporated by reference to Exhibit 10.48 to our Form 10-Q filed February 10, 2020). Exhibit 10.48 PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, ACURA PHARMACEUTICALS, INC., a New York corporation with offices located at 616 N. North Court, Suite 120, Palatine, Illinois (“Borrower”), hereby unconditionally promises to pay to the order of John Schutte c/o MainPointe Pharmaceuticals, LLC, 333 E. Main Street, Louisville, KY 40202 or his
January 2, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): January 2, 2020 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State or other jurisdiction of (Commission File Number
January 2, 2020	EX-99.1	Acura Pharmaceuticals Provides an Update on the Development of LTX-03 Exhibit 99.1 Acura Pharmaceuticals Provides an Update on the Development of LTX-03 PALATINE, IL, January 2, 2020: Acura Pharmaceuticals, Inc. (OTC Pink: ACUR), today provided an update on its development of LTX-03 (Hydrocodone Bitartrate and Acetaminophen) Tablets using Acura’s LIMITx™ technology intended to mitigate risks associated with overdose of the hydrocodone. In conjunction with a third pa
November 8, 2019	NT 10-Q	ACUR / Acura Pharmaceuticals, Inc. NT 10-Q - - NT 10-Q OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 1-10113 CUSIP NUMBER NOTIFICATION OF LATE FILING 00509L 802 (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: September 3
October 4, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): October 1, 2019 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State of Other Jurisdiction (Commission File Number) (
October 4, 2019	EX-99.1	Acura Pharmaceuticals Announces First Quarter 2019 Financial Results EX-99.1 2 tv530683ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Acura Pharmaceuticals Announces First Quarter 2019 Financial Results Palatine, IL – (October 1, 2019) - Acura Pharmaceuticals, Inc., a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse announ
October 1, 2019	EX-10.46	Promissory Note dated March 25, 2019 issued to John Schutte (incorporated by reference to Exhibit 10.46 to our Form 10-Q filed October 1, 2019). Exhibit 10.46 PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, ACURA PHARMACEUTICALS, INC., a New York corporation with offices located at 616 N. North Court, Suite 120, Palatine, Illinois (“Borrower”), hereby unconditionally promises to pay to the order of John Schutte c/o MainPointe Pharmaceuticals, LLC, 333 E. Main Street, Louisville, KY 40202 or his
October 1, 2019	10-Q	ACUR / Acura Pharmaceuticals, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 Or ¨ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-10113 Acura Pharm
September 17, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): September 16, 2019 ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as specified in its Charter) New York 1-10113 11-0853640 (State of Other Jurisdiction (Commission File Number
September 17, 2019	EX-99.1	Acura Pharmaceuticals Announces Fourth Quarter 2018 and Full Year 2018 Financial Results EX-99.1 2 tv529507ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Acura Pharmaceuticals Announces Fourth Quarter 2018 and Full Year 2018 Financial Results Palatine, IL – (September 16, 2019) - Acura Pharmaceuticals, Inc., a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated wit
September 16, 2019	EX-10.42	Promissory Note dated October 5, 2018 issued to John Schutte (incorporated by reference to Exhibit 10.42 to our Form 10-K filed September 16, 2019). Exhibit 10.42 PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, ACURA PHARMACEUTICALS, INC., a New York corporation with offices located at 616 N. North Court, Suite 120, Palatine, Illinois (“Borrower”), hereby unconditionally promises to pay to the order of John Schutte c/o MainPointe Pharmaceuticals, LLC, 333 E. Main Street, Louisville, KY 40202 or his
September 16, 2019	EX-10.43	Promissory Note dated November 21, 2018 issued to John Schutte (incorporated by reference to Exhibit 10.43 to our Form 10-K filed September 16, 2019). Exhibit 10.43 PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, ACURA PHARMACEUTICALS, INC., a New York corporation with offices located at 616 N. North Court, Suite 120, Palatine, Illinois (“Borrower”), hereby unconditionally promises to pay to the order of John Schutte c/o MainPointe Pharmaceuticals, LLC, 333 E. Main Street, Louisville, KY 40202 or his
September 16, 2019	EX-10.45	Promissory Note dated January 28, 2019 issued to John Schutte (incorporated by reference to Exhibit 10.45 to our Form 10-K filed September 16, 2019). Exhibit 10.45 PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, ACURA PHARMACEUTICALS, INC., a New York corporation with offices located at 616 N. North Court, Suite 120, Palatine, Illinois (“Borrower”), hereby unconditionally promises to pay to the order of John Schutte c/o MainPointe Pharmaceuticals, LLC, 333 E. Main Street, Louisville, KY 40202 or his
September 16, 2019	10-K	ACUR / Acura Pharmaceuticals, Inc. 10-K - Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2018 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-10113 ACURA PHARMACEUTI
September 16, 2019	EX-10.44	Promissory Note dated December 20, 2018 issued to John Schutte (incorporated by reference to Exhibit 10.44 to our Form 10-K filed September 16, 2019). Exhibit 10.44 PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, ACURA PHARMACEUTICALS, INC., a New York corporation with offices located at 616 N. North Court, Suite 120, Palatine, Illinois (“Borrower”), hereby unconditionally promises to pay to the order of John Schutte c/o MainPointe Pharmaceuticals, LLC, 333 E. Main Street, Louisville, KY 40202 or his
August 7, 2019	EX-99	AMENDED, CONSOLIDATED AND RESTATED CONVERTIBLE SECURED PROMISSORY NOTE June 28, 2019 Exhibit 99.4 THIS NOTE AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTION 9.2 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER THE SECURITIES ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM A
August 7, 2019	EX-99	Assignment of Promissory Note, Warrant and Security Agreement EX-99 4 acuraex99-6.htm EXHIBIT 99.6 Exhibit 99.6 Assignment of Promissory Note, Warrant and Security Agreement For value received, John Schutte (“Assignor”) hereby assigns and transfers to Abuse Deterrent Pharma, LLC, a Kentucky limited liability company (“Assignee”), all of the Assignor’s right, title and interest in and to (i) that certain Amended, Consolidated and Restated Convertible Secured
August 7, 2019	EX-99	COMMON STOCK PURCHASE WARRANT Exhibit 99.5 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTION 5.3 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATIS
August 7, 2019	EX-99	AGREEMENT AMONG REPORTING PERSONS Exhibit 99.7 AGREEMENT AMONG REPORTING PERSONS THIS AGREEMENT AMONG REPORTING PERSONS is made and entered into by and among John Schutte (“Schutte”), an individual, and Abuse Deterrent Pharma, LLC, a Kentucky limited liability company (“AD Pharma"). W I T N E S S E T H : WHEREAS, each of Schutte and AD Pharma be deemed to beneficially own shares of the Common Stock of Acura Pharmaceuticals, Inc.,
August 7, 2019	SC 13D/A	ACUR / Acura Pharmaceuticals, Inc. / Schutte John - ACURA PHARMACEUTICALS SC13DA-1 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ACURA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00509L802 (CUSIP Number) John Schutte c/o Main Pointe Pharmaceuticals, LLC 333 W. Main Street, Suite 200 Louisville, KY 40202 502-423-0351 (Name, Address and Telep
August 6, 2019	NT 10-Q	ACUR / Acura Pharmaceuticals, Inc. NT 10-Q - - NT 10-Q OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 1-10113 CUSIP NUMBER NOTIFICATION OF LATE FILING 00509L 802 (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K [√] Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: June 30,
July 5, 2019	EX-99.1	Acura Pharmaceuticals Licenses LIMITx™ LTX-03 Agreement Provides For Completion of Development and Commercialization Transaction Valued at up to $21.3 Million, not including Royalties Exhibit 99.1 Acura Pharmaceuticals Licenses LIMITx™ LTX-03 Agreement Provides For Completion of Development and Commercialization Transaction Valued at up to $21.3 Million, not including Royalties PALATINE, IL, July 2, 2019: Acura Pharmaceuticals, Inc. (OTC Pink: ACUR) today announced a License, Development and Commercialization Agreement (the "Agreement") with Abuse Deterrent Pharmaceuticals, LLC
July 5, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 June 28, 2019 Date of Report (Date of earliest event reported) ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) State of New York 1-10113 11-0853640 (State of Other Jurisdiction (Commission File Number)
June 12, 2019	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 June 12, 2019 Date of Report (Date of earliest event reported) ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) State of New York 1-10113 11-0853640 (State of Other Jurisdiction (Commission File Number)
May 7, 2019	NT 10-Q	ACUR / Acura Pharmaceuticals, Inc. NT 10-Q NT 10-Q OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 1-10113 CUSIP NUMBER NOTIFICATION OF LATE FILING 00509L 802 (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K [✓] Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: March 31,
May 3, 2019	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 May 1, 2019 Date of Report (Date of earliest event reported) ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) State of New York 1-10113 11-0853640 (State of Other Jurisdiction (Commission File Number) (
April 1, 2019	NT 10-K	ACUR / Acura Pharmaceuticals, Inc. NT 10-K OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 1-10113 CUSIP NUMBER NOTIFICATION OF LATE FILING 00509L 802 (Check one): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31
March 28, 2019	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 March 25, 2019 Date of Report (Date of earliest event reported) ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) State of New York 1-10113 11-0853640 (State of Other Jurisdiction of Incorporation) (Comm
January 30, 2019	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 January 28, 2019 Date of Report (Date of earliest event reported) ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) State of New York 1-10113 11-0853640 (State of Other Jurisdiction (Commission File Numb
December 21, 2018	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 December 20, 2018 Date of Report (Date of earliest event reported) ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) State of New York 1-10113 11-0853640 (State of Other Jurisdiction (Commission File Num
November 27, 2018	EX-99.1	Acura Pharmaceuticals Announces Third Quarter 2018 Financial Results Exhibit 99.1 Acura Pharmaceuticals Announces Third Quarter 2018 Financial Results Palatine, IL – (November 27, 2018) - Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and nine months ended September 30, 2018. The Company reported a net loss of $1.1 million or $0.05 per diluted share for
November 27, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 November 27, 2018 Date of Report (Date of earliest event reported) ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) State of New York 1-10113 11-0853640 (State of Other Jurisdiction (Commission File Num
November 27, 2018	EX-10.39	Promissory Note dated August 2, 2018 issued to John Schutte (incorporated by reference to Exhibit 10.39 to our Form 10-Q filed November 27, 2018). Exhibit 10.39 THIS PROMISSORY NOTE (AND ALL PAYMENT AND ENFORCEMENT PROVISIONS HEREIN) (THE “NOTE”) IS SUBJECT TO THE TERMS OF A SUBORDINATION AGREEMENT DATED AS OF MAY 7, 2018, BY AND AMONG OXFORD FINANCE LLC, AS COLLATERAL AGENT, THE NOTEHOLDER (AS DEFINED HEREIN), THE LENDERS THAT ARE PARTY TO THE LOAN AGREEMENT (AS DEFINED HEREIN), AND THE BORROWER (AS DEFINED HEREIN) (THE “SUBORDINATION AGREE
November 27, 2018	10-Q	ACUR / Acura Pharmaceuticals, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2018 Or ¨ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-10113 Acura
November 27, 2018	EX-10.40	Promissory Note dated September 13, 2018 issued to John Schutte (incorporated by reference to Exhibit 10.40 to our Form 10-Q filed November 27, 2018). Exhibit 10.40 THIS PROMISSORY NOTE (AND ALL PAYMENT AND ENFORCEMENT PROVISIONS HEREIN) (THE “NOTE”) IS SUBJECT TO THE TERMS OF A SUBORDINATION AGREEMENT DATED AS OF MAY 7, 2018, BY AND AMONG OXFORD FINANCE LLC, AS COLLATERAL AGENT, THE NOTEHOLDER (AS DEFINED HEREIN), THE LENDERS THAT ARE PARTY TO THE LOAN AGREEMENT (AS DEFINED HEREIN), AND THE BORROWER (AS DEFINED HEREIN) (THE “SUBORDINATION AGREE
November 26, 2018	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 November 21, 2018 Date of Report (Date of earliest event reported) ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) State of New York 1-10113 11-0853640 (State of Other Jurisdiction (Commission File Num
November 14, 2018	NT 10-Q	ACUR / Acura Pharmaceuticals, Inc. FORM NT 10-Q UNITED STATESSECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 1-10113 CUSIP Number: 00509L 802 NOTIFICATION OF LATE FILING (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K þ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: September 30, 2018 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11
October 9, 2018	EX-99.1	Acura Pharmaceuticals, Inc. Restructures Debt Obligations Exhibit 99.1 Acura Pharmaceuticals, Inc. Restructures Debt Obligations Palatine, IL – October 9, 2018 - Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company focused on innovating abuse deterrent drugs, today announced that on October 5, 2018 we restructured our debt obligations by (a) receiving an additional $1.8 million loan from John Schutte and (b) retiring in full our
October 9, 2018	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 October 5, 2018 Date of Report (Date of earliest event reported) ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) State of New York 1-10113 11-0853640 (State of Other Jurisdiction (Commission File Numbe
September 14, 2018	8-K	Entry into a Material Definitive Agreement, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 September 5, 2018 Date of Report (Date of earliest event reported) ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) State of New York 1-10113 11-0853640 (State of Other Jurisdiction (Commission File Num
August 14, 2018	EX-99.1	Acura Pharmaceuticals Announces Second Quarter 2018 Financial Results Exhibit 99.1 Acura Pharmaceuticals Announces Second Quarter 2018 Financial Results Palatine, IL – (August 14, 2018) - Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and six months ended June 30, 2018. The Company reported a net loss of $2.8 million or $0.13 per diluted share for the six
August 14, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 August 14, 2018 Date of Report (Date of earliest event reported) ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) State of New York 1-10113 11-0853640 (State of Other Jurisdiction of Incorporation) (Com
August 14, 2018	10-Q	ACUR / Acura Pharmaceuticals, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2018 Or ¨ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-10113 Acura Pharm
August 14, 2018	EX-10.37	Fourth Amendment dated as of June 6, 2018 to Loan and Security Agreement dated as of December 27, 2013, as amended, between the Registrant, Acura Pharmaceutical Technologies, Inc. and Oxford Finance, LLC (incorporated by reference to Exhibit 10.37 to our Form 10-Q filed August 14, 2018). Exhibit 10.37 Execution Version FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of June 6, 2018 (the “Fourth Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (in its individual capacity, “Oxf
August 14, 2018	EX-10.35	Promissory Note dated May 7, 2018 issued to John Schutte (incorporated by reference to Exhibit 10.35 to our Form 10-Q filed August 14, 2018). Exhibit 10.35 THIS PROMISSORY NOTE (AND ALL PAYMENT AND ENFORCEMENT PROVISIONS HEREIN) (THE “NOTE”) IS SUBJECT TO THE TERMS OF A SUBORDINATION AGREEMENT DATED AS OF MAY 7, 2018, BY AND AMONG OXFORD FINANCE LLC, AS COLLATERAL AGENT, THE NOTEHOLDER (AS DEFINED HEREIN), THE LENDERS THAT ARE PARTY TO THE LOAN AGREEMENT (AS DEFINED HEREIN), AND THE BORROWER (AS DEFINED HEREIN) (THE “SUBORDINATION AGREE
August 14, 2018	EX-10.36	Subordination Agreement dated as of May 7, 2018 between John Schutte and Oxford Finance, LLC, approved by Registrant and Acura Pharmaceutical Technologies, Inc. (incorporated by reference to Exhibit 10.36 to our Form 10-Q filed August 14, 2018). Exhibit 10.36 Execution Version SUBORDINATION AGREEMENT This Subordination Agreement (the “Agreement”) is made as of May 7, 2018, by and between JOHN SCHUTTE, an individual (the “Creditor”), and OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314, in its capacity as Collateral Agent (as hereinafter defined) for the
August 14, 2018	EX-10.38	Promissory Note dated June 28, 2018 issued to John Schutte (incorporated by reference to Exhibit 10.38 to our Form 10-Q filed August 14, 2018). Exhibit 10.38 THIS PROMISSORY NOTE (AND ALL PAYMENT AND ENFORCEMENT PROVISIONS HEREIN) (THE “NOTE”) IS SUBJECT TO THE TERMS OF A SUBORDINATION AGREEMENT DATED AS OF MAY 7, 2018, BY AND AMONG OXFORD FINANCE LLC, AS COLLATERAL AGENT, THE NOTEHOLDER (AS DEFINED HEREIN), THE LENDERS THAT ARE PARTY TO THE LOAN AGREEMENT (AS DEFINED HEREIN), AND THE BORROWER (AS DEFINED HEREIN) (THE “SUBORDINATION AGREE
August 3, 2018	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 August 2, 2018 Date of Report (Date of earliest event reported) ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) State of New York 1-10113 11-0853640 (State of Other Jurisdiction (Commission File Number
July 31, 2018	RW	ACUR / Acura Pharmaceuticals, Inc. RW July 31, 2018 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey Gabor, Esq. Re: Acura Pharmaceuticals, Inc. (the “Company”) Registration Statement on Form S-1, File No. 333-215885 Request for Withdrawal Ladies and Gentleman: The Company hereby applies for withdrawal of the Company’s Registration Statement (File No. 333-215885) on Form S-1 filed wi
June 29, 2018	EX-99.1	Acura Pharmaceuticals Announces First Quarter 2018 Financial Results EX-99.1 2 tv497559ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Acura Pharmaceuticals Announces First Quarter 2018 Financial Results Palatine, IL – (June 29, 2018) - Acura Pharmaceuticals, Inc. (OTC PINK: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three months ended March 31, 2018. The Company reported for the first quarter 2018 a n
June 29, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 June 29, 2018 Date of Report (Date of earliest event reported) ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) State of New York 1-10113 11-0853640 (State of Other Jurisdiction of Incorporation) (Commi
June 29, 2018	10-Q	ACUR / Acura Pharmaceuticals, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2018 Or ¨ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-10113 Acura Phar
June 28, 2018	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 June 28, 2018 Date of Report (Date of earliest event reported) ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) State of New York 1-10113 11-0853640 (State of Other Jurisdiction of Incorporation) (Commi
June 7, 2018	EX-99.1	Acura Pharmaceuticals Announces Fourth Quarter 2017 and Full Year 2017 Financial Results Exhibit 99.1 Acura Pharmaceuticals Announces Fourth Quarter 2017 and Full Year 2017 Financial Results Palatine, IL – (June 7, 2018) - Acura Pharmaceuticals, Inc. (OTC PINK: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and twelve months ended December 31, 2017. The Company reported a net loss of $5.7 million or $0.36 per
June 7, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 June 7, 2018 Date of Report (Date of earliest event reported) ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) State of New York 1-10113 11-0853640 (State of Other Jurisdiction (Commission File Number)
June 7, 2018	EX-10.34	License, Commercialization and Option Agreement is made and entered into as of March 16, 2017 by and between MainPointe Pharmaceuticals, LLC (incorporated by reference to Exhibit 10.34 to our Form 10-K filed June 7, 2018). EX-10.34 2 tv490022ex10-34.htm EXHIBIT 10.34 Exhibit 10.34 EXECUTION COPY LICENSE, COMMERCIALIZATION AND OPTION AGREEMENT This License, Commercialization and Option Agreement (“Agreement”) is made and entered into as of March 16, 2017 (the “Effective Date”) by and between MainPointe Pharmaceuticals, LLC, with offices at 333 East Main Street, Suite 220, Louisville, Kentucky 40202 (“MainPointe”), an
June 7, 2018	10-K	ACUR / Acura Pharmaceuticals, Inc. FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2017 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-10113 ACURA PHARMACEUTI
June 6, 2018	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 June 1, 2018 Date of Report (Date of earliest event reported) ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) State of New York 1-10113 11-0853640 (State of Other Jurisdiction of Incorporation) (Commis
June 4, 2018	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 June 4, 2018 Date of Report (Date of earliest event reported) ACURA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) State of New York 1-10113 11-0853640 (State of Other Jurisdiction of Incorporation) (Commis

ACUR / Acura Pharmaceuticals, Inc. - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

Grundläggande statistik

SEC Filings

SEC Filings (Chronological Order)